UPDATE 1 — BioNTech's mRNA cancer therapy misses first goal in head and neck trial
(Updates share movement, adds details and analyst comment in bullets 5 and 6) Oct 13 (Reuters) — BioNTech said on Tuesday its experimental mRNA cancer immunotherapy failed to meet the first main goal of a mid-to-late-stage trial in patients with head and neck cancer. US-listed shares of the drug developer were down nea